Angiogenesis inhibitors in the treatment of prostate cancer.
about
DW-MRI of the urogenital tract: applications in oncology.Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Current treatment strategies for castration-resistant prostate cancerTargeting angiogenesis for the treatment of prostate cancer.Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.Adiponectin inhibits VEGF-A in prostate cancer cells.A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer.Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A.Emerging treatments for castrate-resistant prostate cancer.Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma.Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function.
P2860
Q34256443-B8DB36E9-1CF0-43E3-8080-07565577FC9FQ34323756-0F52A6CD-21D8-4D6F-9129-2B400952F06FQ37111160-E0DBF2EF-DA8F-425F-8D34-809A26FAC680Q37117375-2A877C12-5A8C-47E4-8A52-D3A2A1980BEDQ37565167-CFE7F1C9-1BD0-45D3-90A2-CE02A1DB93F2Q37823843-052C76AD-8CB1-4BA1-8141-6F7B2E7E4CC4Q37827186-7409D858-C4C4-4945-A0DC-2388C821669DQ37860950-EFDE5B45-7A22-4F8B-9D5C-05FFC8B85412Q37993137-61B1D63E-BA85-4555-82C8-74407A4F997CQ38772275-AB5F6623-050A-4056-83AF-5BAEB27C6149Q38920281-F63ABA08-153E-448E-B706-0797F745EA97Q40182500-27447C62-95FD-4954-8D4A-9DC3CA7F26EEQ40414177-941BFE16-3806-4851-9F6A-2BC9D531AD73Q41692367-6E2DA8E5-AD87-45AA-A87E-01A569F0EFF0Q44336766-346B657E-BDBD-44BC-8CB8-D655CA9ADCE6Q46495042-31E20F8C-FF56-4649-B281-B2AF3BC82A50Q47576130-A8451D55-7EC4-4765-90C6-853CE9B28B07Q55256331-211582A9-8722-4EC3-A373-4357BF599435
P2860
Angiogenesis inhibitors in the treatment of prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Angiogenesis inhibitors in the treatment of prostate cancer.
@ast
Angiogenesis inhibitors in the treatment of prostate cancer.
@en
type
label
Angiogenesis inhibitors in the treatment of prostate cancer.
@ast
Angiogenesis inhibitors in the treatment of prostate cancer.
@en
prefLabel
Angiogenesis inhibitors in the treatment of prostate cancer.
@ast
Angiogenesis inhibitors in the treatment of prostate cancer.
@en
P2093
P2860
P1476
Angiogenesis inhibitors in the treatment of prostate cancer.
@en
P2093
Paul G Kluetz
William D Figg
William L Dahut
P2860
P304
P356
10.1517/14656560903451716
P407
P577
2010-02-01T00:00:00Z